第二原发肺癌——肺癌幸存者中日益突出的问题
随着肺癌筛查和治愈性治疗手段的进步,5年生存率不断提高,长期幸存者面临第二原发肺癌(SPLC)风险。本综述梳理了SPLC监测、诊断和管理的挑战,指出近5年随访中最多1/6的长期幸存者可能发生SPLC,基因组方法有助于区分SPLC与第一原发灶的肺内转移,基于血液的早期检测生物标志物正在多中心前瞻性研究中评估。
要点
- 长期肺癌幸存者中SPLC发生率可能高于既往认识,部分与多灶性腺癌谱疾病增加有关
- 准确区分SPLC与第一原发肺癌复发至关重要,因两者管理策略截然不同
- 基因组方法有助于鉴别SPLC与肺内转移,基于血液的生物标志物正在多中心前瞻性研究中评估
核心结论
- SPLC是肺癌幸存者中日益突出的问题,需要结合临床病史、组织病理学评估和基因组分析更新分类方法,并探索早期检测生物标志物的作用。
研究设计与样本
- 本综述基于前瞻性随访研究的最新数据,探讨SPLC的监测、诊断和管理挑战,并回顾基因组方法和早期检测生物标志物的潜在作用。
主要发现
- 前瞻性随访研究的最新数据提示,SPLC的发病率可能高于既往认识,部分归因于多灶性腺癌谱疾病的增加。
- 在5年以上,最多每6名长期肺癌幸存者中就有1名可能发生SPLC。
- 基因组方法目前尚未常规用于临床实践,但正在兴起,可用于区分SPLC与第一原发灶的肺内转移。
- 将SPLC错误分类为第一原发灶复发可能对患者管理和总生存产生重大影响。
关键数值与推荐
- 在5年以上,最多1/6的长期肺癌幸存者可能发生SPLC。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As a result of an increased focus on early detection including lung cancer screening, combined with more curative treatment options, the 5-year survival rates for lung cancer are improving. Welcome though this is, it brings new, hitherto unseen challenges. As more patients are cured and survive longer, they are at risk of developing second primary cancers, particularly lung cancer. In this review, we examine the challenges that surveillance, diagnosis, and management of second primary lung cancer (SPLC) bring and how these can be addressed. Recent data from prospective follow-up studies suggests that the incidence of SPLC may be higher than previously appreciated, partly due to an increase in multi-focal adenocarcinoma spectrum disease. Over 5 years, up to 1 in 6 long-term lung cancer survivors may develop a SPLC. Although not routinely used in clinical practice at present, genomic approaches for differentiating SPLC from intrapulmonary metastases of the first primary are emerging, and we highlight how this could be used to help differentiate lesions. An accurate distinction between SPLC and the recurrence of the first primary is of paramount importance due to the very different management strategies that may be required. Wrongly classifying an SPLC as a recurrence of the first primary may have significant consequences for patient management and overall survival. Updated approaches to the classification of SPLC combining clinical history, histopathological assessment, and genomic profiling are needed. Finally, we review the potential role of early detection biomarkers in the identification of SPLC, focusing in particular on blood-based biomarkers that are being examined in a multi-center prospective study recruiting lung cancer survivors.
引用
- Jensen SØ, Moore DA, Surani AA, et al. Second Primary Lung Cancer - An Emerging Issue in Lung Cancer Survivors. J Thorac Oncol. 2024. PMID: 39059487. doi:10.1016/j.jtho.2024.07.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。